

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
02410399AA

In Re Application Of: **Hirofumi TACHIBANA**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/551,469	September 30, 2005	unknown	30743	1614	4441

**Title: METHOD OF SCREENING DRUG WITH THE USE OF 67kDa LAMININ RECEPTOR AND DRUG OBTAINED THEREBY**

Address to:  
**Commissioner for Patents**  
P.O. Box 1450  
Alexandria, VA 22313-1450

**37 CFR 1.97(b)**

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

**OR**

the fee set forth in 37 CFR 1.17(p).

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of

Hirofumi Tachibana

Confirmation No.:4441

Serial No. 10/551,469

Group Art Unit: 1614

Filed: September 30, 2005

Examiner: unknown

For: METHOD OF SCREENING DRUG WITH THE USE OF 67kDa LAMININ  
RECEPTOR AND DRUG OBTAINED THEREBY

Commissioner for Patents

PO Box 1450

Alexandria, Virginia 22313-1450

**INFORMATION DISCLOSURE STATEMENT**


Sir:

Under the provisions of 37 C.F.R. §1.97 through §1.98 and pursuant to applicant's duty of disclosure under 37 C.F.R. §1.56, applicant respectfully brings the following documents, cited in the partial European Search Report for the above-identified patent application dated March 13, 2007, and listed on the attached forms PTO-1449, to the attention of the Examiner in charge of the above-identified application.

This citation does not constitute an admission that the references are relevant or material to the claims. They are only cited as constituting related art of which the applicant is aware.

It is respectfully requested that the listed references be formally made of record in the application. Please charge any deficiencies in fees and credit any overpayment of fees to the Attorney's Deposit Account No. 50-2041 (Whitham, Curtis, Christofferson & Cook, P.C.).

Respectfully submitted,

  
Olga V. Merkulova

Reg. No. 48,757

Whitham, Curtis & Christofferson, P.C.  
11491 Sunset Hills Road, Suite 340  
Reston, VA 20190  
Tel. (703) 787-9400  
Fax. (703) 787-7557  
Customer No.: 30743

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY DOCKET NO.	APPLICATION NO.	
			02410399AA	10/551,469	
			APPLICANT(S) <b>Hiromi TACHIBANA</b>		
FILING DATE <b>September 30, 2005</b>	GROUP ART UNIT <b>1614</b>				

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US 6,410,052 B1	06/25/2002	Morre et al.	424	468	08/10/2000

## U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES      NO

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	A copy of the Supplementary European Search Report dated March 13, 2007, pages 1-5
	Hou et al.: "Effects of tea polyphenols on signal transduction pathways related to cancer chemoprevention", MUTATION RESEARCH, AMSTERDAM, NL, vol.555, no. 1-2, November 2, 2004; pages 3-19
	NARUMI et al.: "Inhibition of experimental metastasis of human fibrosarcoma cells by anti-recombinant 37-kDa Taminin binding protein antibody", JAPANESE JOURNAL OF CANCER RESEARCH, JAPANESE CANCER ASSOCIATION, TOKYO, JP, vol. 90, no. 4, April 1999, pages 425-431

EXAMINER	DATE CONSIDERED
/Minh Tam Davis/ (07/16/2008)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				ATTY DOCKET NO. 02410399AA	APPLICATION NO. 10/551,469	
				Hirofumi TACHIBANA		
				FILING September 30, 2005	GROUP ART 1614	
U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
U.S. PATENT APPLICATION PUBLICATIONS						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	GEVAROWSKA DOROTA ET AL.: "Synthetic peptides interacting with the 67-kd laminin receptor can reduce retinal ischemia and inhibit hypoxia-induced retinal neovascularization", AMERICAN JOURNAL OF PATHOLOGY, vol. 160, no. 1, January 2002, pages 307-313					
	TANAKA MASASHI ET AL.: "Expression of the 37-kDa laminin binding protein in murine lung tumor cell correlates with tumor angiogenesis", CANCER LETTERS, vol. 153, no. 1-2, May 29, 2000, pages 161-168 KOO ET AL.: "Pharmacological effects of green tea on the gastrointestinal system", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL., vol.500, no. 1-3, October 1, 2004, pages 177-185					
EXAMINER	/Minh Tam Davis/ (07/16/2008)		DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>				ATTY DOCKET NO.	APPLICATION NO.		
				02410399AA		10/551,469	
				<b>Hirofumi TACHIBANA</b> <b>FILING</b> <b>September 30, 2005</b>		<b>GROUP ART</b> <b>1614</b>	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<b>U.S. PATENT APPLICATION PUBLICATIONS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	<b>TRANSLATION</b> YES      NO
<b>OTHER DOCUMENTS</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
		KOO et al.: "Pharmacological effects of green tea on the gastrointestinal system", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 500, No. 1-3, October 1, 2004, pages 177-185					
EXAMINER    /Minh Tam Davis/ (07/16/2008)				DATE CONSIDERED			

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.